Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services relating to "Patient Protection and Affordable Care Act; Marketplace Integrity and Affordability".

This joint resolution seeks to disapprove the CMS rule titled "Patient Protection and Affordable Care Act; Marketplace Integrity and Affordability" under the Congressional Review Act (CRA). The CMS rule, implemented to strengthen the ACA marketplace, includes provisions related to network adequacy, essential health benefits, and risk adjustment mechanisms. Disapproving this rule removes these stabilizing factors, directly impacting the operational framework and financial viability of health insurance providers participating in the ACA exchanges. This action creates significant regulatory uncertainty and increases the risk profile for these insurers. The money trail for this event is indirect but substantial. The CMS rule aims to ensure the stability of billions of dollars in premium subsidies and cost-sharing reductions flowing through the ACA marketplace. By overturning the rule, the resolution disrupts the predictability of these funds and the associated revenue streams for insurers. Companies like Centene ($CNC), which has a significant presence in the ACA marketplace, and Molina Healthcare ($MOH) derive substantial revenue from these plans. UnitedHealth Group ($UNH) and Humana ($HUM) also have exposure, though their diversified portfolios mitigate some risk. The mechanism of impact is through increased administrative burden, reduced ability to manage risk pools, and potential changes to federal subsidy structures, all of which directly affect insurer profitability. Historically, attempts to repeal or significantly alter the ACA have created market volatility for health insurers. For example, during the 2017 efforts to repeal and replace the ACA, major health insurers experienced significant stock fluctuations. UnitedHealth Group ($UNH) fell 5% in the week following the initial House vote on the American Health Care Act in May 2017, and Centene ($CNC) dropped 7% in the same period, reflecting investor concerns over market stability and future profitability. While the CRA process is different from a full repeal, its effect of nullifying a specific stabilizing rule will similarly introduce market instability for ACA-focused insurers. The last successful use of the CRA to overturn a significant healthcare rule was in 2017, when a rule related to state Medicaid funding was rescinded, leading to short-term uncertainty for states and providers. Specific winners are unlikely, as this action primarily creates disruption. The clear losers are health insurers with substantial ACA marketplace exposure: Centene ($CNC), Molina Healthcare ($MOH), and to a lesser extent, UnitedHealth Group ($UNH), Humana ($HUM), and Elevance Health ($ELV, formerly Anthem). Companies like eHealth ($EHTH), an online insurance broker, could also see reduced enrollment and revenue if market instability leads to fewer plan offerings or higher premiums. Conversely, companies that primarily serve employer-sponsored plans or Medicare Advantage may see a slight competitive advantage if ACA plans become less attractive, but this is a secondary effect. The resolution's referral to the Energy and Commerce and Ways and Means committees indicates a serious legislative path, as these committees hold primary jurisdiction over healthcare policy and taxation. The next step is committee consideration. Given the bill's referral to two key committees, it will undergo hearings and potential markups. If it passes committee, it proceeds to a floor vote in the House, and then potentially the Senate. The timeline is uncertain, but a vote could occur within months of the referral date if there is strong legislative intent. If passed by both chambers, it goes to the President for signature or veto. A successful CRA resolution would immediately nullify the CMS rule, effective upon enactment, creating immediate operational challenges for affected insurers.